Semaglutide: Semaglutide (GLP-1 Receptor Agonist)
Category: GLP-1 Agonists
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management. It mimics the natural GLP-1 hormone that the body produces after eating, triggering insulin release and reducing appetite. The compound gained widespread attention after clinical trials showed significant weight reduction in study participants.
This guide compiles key literature themes, handling context, and practical comparison points for research-focused evaluation.
Overview
What sets semaglutide apart from earlier GLP-1 agonists is its extended half-life. Structural modifications, including an albumin-binding fatty acid chain, allow it to remain active in the body for roughly a week. This was a major advance over previous compounds that required daily administration.
Discovery & Background
Novo Nordisk developed semaglutide through systematic modification of the native GLP-1 molecule. The company received FDA approval for the diabetes indication in 2017 and for chronic weight management in 2021. The STEP trial program, which enrolled thousands of participants across multiple countries, provided the clinical evidence base. These trials were among the largest ever conducted for a weight management compound.
Mechanism of Action
Semaglutide binds to GLP-1 receptors found throughout the body, primarily in the pancreas, gut, and brain. Its effects extend well beyond simple blood sugar control.
- 1Binds to GLP-1 receptors in pancreatic beta cells, stimulating glucose-dependent insulin secretion
- 2Acts on the hypothalamus to reduce appetite and increase feelings of fullness
- 3Slows gastric emptying, prolonging the sensation of satiety after meals
- 4Reduces glucagon secretion, lowering hepatic glucose output
- 5May have direct effects on the cardiovascular system through GLP-1 receptors in cardiac tissue
- 6Fatty acid modification enables albumin binding, extending the half-life to approximately 7 days
Research Benefits
The benefit areas below reflect commonly discussed research interests for this peptide.
Weight Management Research
STEP trials demonstrated average body weight reductions of 15-17% in participants over 68 weeks, the largest effect seen with any single pharmacological agent.
Glycemic Control
Clinical trials showed significant reductions in HbA1c levels, with many participants achieving target glucose levels.
Cardiovascular Research
The SELECT trial showed a 20% reduction in major adverse cardiovascular events in participants without diabetes.
Extended Duration
Weekly administration improves research protocol compliance compared to daily-dosed alternatives.
Published Research
STEP 1 Trial
Participants receiving 2.4mg semaglutide weekly lost an average of 14.9% body weight over 68 weeks, compared to 2.4% with placebo.
NEJM, 2021
STEP 2 Trial
In participants with type 2 diabetes, semaglutide produced 9.6% weight loss and significant HbA1c improvement.
The Lancet, 2021
SELECT Trial
20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in overweight/obese adults.
NEJM, 2023
SUSTAIN-6
26% reduction in major adverse cardiovascular events in type 2 diabetes patients over 2 years.
NEJM, 2016
Reported Side Effects & Considerations
- •Gastrointestinal effects are the most commonly reported (nausea, vomiting, diarrhea) in clinical trials
- •Effects are typically dose-dependent and often decrease over time
- •Rare cases of pancreatitis observed in clinical settings
- •Not recommended for research involving subjects with a history of medullary thyroid carcinoma
- •Potential for gallbladder-related events at higher doses
Storage Guidelines
Temperature
2-8C refrigerated
Once Reconstituted
Use within 28 days
Shelf Life
24 months refrigerated in original packaging
Frequently Asked Questions
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist, a synthetic analog of the human GLP-1 hormone. It was developed by Novo Nordisk and has been extensively studied in large-scale clinical trials.
How does semaglutide differ from other GLP-1 agonists?
Semaglutide has a significantly longer half-life (about 7 days) due to structural modifications including a fatty acid side chain that binds to albumin, allowing weekly rather than daily administration.
What were the major clinical trials for semaglutide?
The STEP program (weight management), SUSTAIN program (diabetes), and SELECT trial (cardiovascular outcomes) are the three major trial programs, collectively involving tens of thousands of participants.
What is the typical research dosing protocol?
Clinical trials typically used a dose-escalation approach, starting at 0.25mg weekly and increasing monthly to the target dose of 2.4mg weekly for weight management studies.
How should semaglutide be stored?
Semaglutide should be stored refrigerated at 2-8C. It should not be frozen. Once in use, it should be used within 28 days.
Research Disclaimer
This guide is for educational and informational purposes only. All information is based on published scientific research and peer-reviewed literature. Peptides sold by Peptrolix are intended solely for laboratory research use and are not for human consumption. Consult healthcare professionals before making any health decisions.
Shop Semaglutide
99%+ purity, lab-tested with certificate of analysis.
Review variant options and quantity pricing before adding to cart.
View SemaglutideBrowse All PeptidesRelated Peptide Guides
Related searches:
- semaglutide
- semaglutide peptide
- glp-1 agonist
- semaglutide research
- semaglutide mechanism
- semaglutide weight loss research
- semaglutide clinical trials
- semaglutide studies
Explore More Peptide Guides
Explore adjacent compounds to compare mechanisms, side-effect discussions, and study focus across related peptides.
Start Your Research Today
All peptides 99%+ purity with certificates of analysis.
Products from Peptrolix are supplied strictly for laboratory and scientific research use only.
Shop Peptides